Intrathecal Drug Administration in Chronic Pain Syndromes

• Published in: Pain practice 2014-06, Vol.14 (5), p.461-476
• Main Authors: Ver Donck, Ann, Vranken, Jan H., Puylaert, Martine, Hayek, Salim, Mekhail, Nagy, Van Zundert, Jan
• Format: Article
• Language: English
• Subjects: Analgesics - administration & dosage; chronic pain; Chronic Pain - diagnosis; Chronic Pain - drug therapy; Chronic Pain - epidemiology; evidence-based medicine; Humans; Injections, Spinal; intrathecal drug administration; morphine; Morphine - administration & dosage; Pain Measurement - drug effects; Pain Measurement - methods; Randomized Controlled Trials as Topic - methods; Syndrome; ziconotide
• ISSN: 1530-7085; 1533-2500
• DOI: 10.1111/papr.12111

Chronic pain may recur after initial response to strong opioids in both patients with cancer and patients without cancer or therapy may be complicated by intolerable side effects. When minimally invasive interventional pain management techniques also fail to provide satisfactory pain relief, continuous intrathecal analgesic administration may be considered. Only 3 products have been officially approved for long‐term intrathecal administration: morphine, baclofen, and ziconotide. The efficacy of intrathecal ziconotide for the management of patients with severe chronic refractory noncancer pain was illustrated in 3 placebo‐controlled trials. A randomized study showed this treatment option to be effective over a short follow‐up period for patients with pain due to cancer or AIDS. The efficacy of intrathecal opioid administration for the management of chronic noncancer pain is mainly derived from prospective and retrospective noncontrolled trials. The effect of intrathecal morphine administration in patients with pain due to cancer was compared with oral or transdermal treatment in a randomized controlled trial, which found better pain control and fewer side effects with intrathecal opioids. Other evidence is derived from cohort studies. Side effects of chronic intrathecal therapy may either be technical (catheter or pump malfunction) or biological (infection). The most troublesome complication is, however, the possibility of granuloma formation at the catheter tip that may induce neurological damage. Given limited studies, the evidence for intrathecal drug administration in patients suffering from cancer‐related pain is more compelling than that of chronic noncancer pain.